Gemma Modinos

Gemma Modinos

Auto-generated profile, based on publicly available information

Gemma Modinos

Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2013 in Cortex
Verified
Journal Article
Closed access
GMGemma Modinos
Gemma Modinos
SCSergi G. Costafreda
Sergi G. Costafreda
MTMarie-José van Tol
Marie-José van Tol
PMPhilip K. McGuire
Philip K. McGuire
AAAndré Aleman
André Aleman
PAPaul Allen
Paul Allen

1 March 2015 in Trends in Neurosciences
Verified
Journal Article
Closed access
GMGemma Modinos
Gemma Modinos
PAPaul Allen
Paul Allen
AGAnthony A. Grace
Anthony A. Grace
PMPhilip McGuire
Philip McGuire

17 February 2023 in Molecular Psychiatry
Verified
Journal Article
Open access
PDF file
KMKate Merritt
Kate Merritt
RMRobert A. McCutcheon
Robert A. McCutcheon
AAAndré Aleman
André Aleman
SASarah Ashley
Sarah Ashley
KBKatherine Beck
Katherine Beck
AEAlice Egerton
Alice Egerton
Glutamatergic dysfunction is implicated in schizophrenia pathoaetiology, but this may vary in extent between patients. It is unclear whether inter-individual variability in glutamate is greater in schizophrenia than the general population. We conducted meta-analyses to assess (1) variability of glutamate measures in patients relative to controls (log coefficient of variation ratio: CVR); (2) standardised mean differences (SMD) using Hedges g; (3) modal distribution of individual-level glutamate data (Hartigan’s unimodality dip test). MEDLINE and EMBASE databases were searched from inception to September 2022 for proton magnetic resonance spectroscopy (1H-MRS) studies reporting glutamate, glutamine or Glx in schizophrenia. 123 studies reporting on 8256 patients and 7532 controls were included. Compared with controls, patients demonstrated greater variability in glutamatergic metabolites in the medial frontal cortex (MFC, glutamate: CVR = 0.15,p < 0.001; glutamine: CVR = 0.15,p = 0.003; Glx: CVR = 0.11,p = 0.002), dorsolateral prefrontal cortex (glutamine: CVR = 0.14,p = 0.05; Glx: CVR = 0.25,p < 0.001) and thalamus (glutamate: CVR = 0.16,p = 0.008; Glx: CVR = 0.19,p = 0.008). Studies in younger, more symptomatic patients were associated with greater variability in the basal ganglia (BG glutamate with age:z = −0.03,p = 0.003, symptoms:z = 0.007,p = 0.02) and temporal lobe (glutamate with age:z = −0.03,p = 0.02), while studies with older, more symptomatic patients associated with greater variability in MFC (glutamate with age:z = 0.01,p = 0.02, glutamine with symptoms:z = 0.01,p = 0.02). For individual patient data, most studies showed a unimodal distribution of glutamatergic metabolites. Meta-analysis of mean differences found lower MFC glutamate (g = −0.15,p = 0.03), higher thalamic glutamine (g = 0.53,p < 0.001) and higher BG Glx in patients relative to controls (g = 0.28,p < 0.001). Proportion of males was negatively associated with MFC glutamate (z = −0.02,p < 0.001) and frontal white matter Glx (z = −0.03,p = 0.02) in patients relative to controls. Patient PANSS total score was positively associated with glutamate SMD in BG (z = 0.01,p = 0.01) and temporal lobe (z = 0.05,p = 0.008). Further research into the mechanisms underlying greater glutamatergic metabolite variability in schizophrenia and their clinical consequences may inform the identification of patient subgroups for future treatment strategies.

1 November 2013 in Schizophrenia Research
Verified
Journal Article
Closed access
GMGemma Modinos
Gemma Modinos
CIConrad Iyegbe
Conrad Iyegbe
DPDiana Maria Pinto Prata
Diana Maria Pinto Prata
MRMargarita Rivera
Margarita Rivera
MKMatthew J. Kempton
Matthew J. Kempton
PMPhilip McGuire
Philip McGuire

1 January 2014 in NeuroImage: Clinical
Verified
Journal Article
Open access
MTMarie-José van Tol
Marie-José van Tol
Lisette Van der MeerLisette Van der Meer
Lisette Van der Meer
RBRichard Bruggeman
Richard Bruggeman
GMGemma Modinos
Gemma Modinos
HKHenderikus Knegtering
Henderikus Knegtering
AAAndré Aleman
André Aleman
Auditory verbal hallucinations (AVH) in schizophrenia (SZ) have been proposed to result from abnormal local, interregional and interhemispheric integration of brain signals in regions involved in language production and perception. This abnormal functional integration may find its base in morphological abnormalities. Structurally, AVHs have been frequently linked to abnormal morphology of the superior temporal gyrus (STG), but only a few studies investigated the relation of hallucination presence with both whole-brain gray matter (GM) and white matter (WM) morphometry. Using a unified voxel-based morphometry-DARTEL approach, we investigated correlates of AVH presence in 51 schizophrenia patients (20 non-hallucinating [SZ -], 31 hallucinating [SZ +]), and included 51 age and sex matched healthy participants. Effects are reported at p < .05 FWE corrected. Patients showed lower GM volume of the left STG than controls, irrespective of AVH presence. In addition, SZ + showed lower GM volume of the left inferior frontal and right parahippocampal gyrus, and higher WM volume of the left postcentral and superior parietal lobule than controls. Finally, volume of the putamen was lower in SZ + compared to SZ -. No effects on corpus callosum morphometry were observed. Delusion severity, general positive and negative symptomatology illness duration, and medication status could not explain the results. Results suggest that STG GM abnormalities underlie the general susceptibility to experience psychotic symptoms and that additional abnormalities in a network of medial temporal, ventrolateral, putaminal, and parietal regions related to verbal memory and speech production may specifically increase the likelihood of experiencing AVH. Future studies should clarify the meaning of morphometry abnormalities for functional interregional communication.

1 January 2011 in Neuropsychology
Verified
Journal Article
Closed access
GMGemma Modinos
Gemma Modinos
RRRemco A Renken
Remco A Renken
JOJohan Ormel
Johan Ormel
AAAndré Aleman
André Aleman
The Cortical Midline Structures (CMS) play a critical role in self-reflection, together with the insula. Abnormalities in self-referential processing and its neural underpinnings have been reported in schizophrenia and at-risk populations, suggesting they might be markers of psychotic vulnerability. Psychometric measures of schizotypal traits may be used to index psychosis proneness (PP) in nonclinical samples. It remains an unresolved question whether differences in self-reflective processing are associated with PP. Six hundred students completed the Community Assessment of Psychic Experiences Questionnaire, positive subscale. Two groups were formed from the extremes of the distribution (total N = 36). fMRI was used to examine CMS/insula function during a self-reflection task. Participants judged personality trait sentences about self and about an acquaintance. High PP subjects attributed less positive traits to others (i.e., acquaintances) than subjects with low PP. Across groups, the contrasts self > semantic and self > other induced activation in CMS and insula, whereas other > semantic did not produce insula activation. Other > self induced posterior cingulate cortex activation in low PP but not in high PP. In addition, high PP subjects showed stronger activation than low PP in left insula during self > semantic. Examining valence effects revealed that high PP individuals showed increased activation in left insula, right dMPFC, and left vMPFC for positive self-related traits, and in bilateral insula, ACC, and right dMPFC for negative self-related traits. The findings suggest that aspects of self-referential processing and underlying brain mechanisms are similar in clinical and subclinical (high PP) forms of psychosis, suggesting that these may be associated with vulnerability to psychosis.